Analysis: the runway and the readout are now on the same clock
The disclosure that governs the rest is the pairing of a cash position running into the fourth quarter of 2027 with a first pivotal interim analysis due in the fourth quarter of 2026. That gap, roughly four quarters between the first pivotal signal and the end of the funded period, is what makes the interim analysis the decisive event rather than one milestone among several. The length of the funded period after the readout sets how much time an ambiguous result would leave before the funding horizon the company has stated.
The Phase 1 efficacy figures need to be read with their denominators visible. An overall response rate of 100 percent is 7 of 7 patients, and the complete remission figure of 57 percent is 4 of 7. Those are the target Phase 2 population, drawn from 45 patients treated overall and 15 at the recommended dose. Numbers on that scale establish that the mechanism produces responses in a heavily pretreated group where 82 percent had already received blinatumomab and 53 percent prior CD19 CAR-T. They do not establish a response rate, and the pivotal Phase 2 exists precisely to convert the first statement into the second.
The revenue line should not be read as a business trend. Revenue fell from 26.9 million dollars to 11.0 million dollars because activity under the AstraZeneca research plans was lower, and recognition follows costs incurred against budgeted costs for each plan. That accounting means revenue rises and falls with work performed, not with commercial progress, and the amendment lifting per-candidate milestones to as much as 253 million dollars sits entirely in the future, contingent on option exercises and development outcomes.
What a careful reader would examine next is the composition of the cash rather than its total. Of the 169 million dollars, 131.1 million sits in fixed-term deposits and 2.3 million is restricted, so the immediately liquid balance is 35.6 million dollars. The runway statement is management’s assessment under a going concern basis, expressed as at least twelve months from board approval of the interim statements, alongside a separate statement that the position funds operations into the fourth quarter of 2027. The two framings are not identical, and the quarterly cash reporting between now and the BALLI-01 interim analysis is where they can be reconciled.
What the documents say
Cellectis (Euronext Growth: ALCLS), which is also listed on Nasdaq under the symbol CLLS, reported cash, cash equivalents and fixed-term deposits of 169 million dollars as of June 30, 2026, and said that position funds operations into the fourth quarter of 2027. The figure was published with second-quarter results on August 6, 2026, and the underlying interim financial statements were furnished to the Securities and Exchange Commission on Form 6-K.
The composition of that cash matters for how it can be used. The interim statements show cash and cash equivalents of 35.6 million dollars and fixed-term bank deposits of 131.1 million dollars at June 30, 2026, the deposits classified as a current financial asset, with restricted cash of 2.3 million dollars included in the headline total.
The two clinical programmes carrying the story
Lasme-cel, an allogeneic CAR-T candidate in relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia, moved furthest. In June 2026 the Food and Drug Administration granted it Regenerative Medicine Advanced Therapy designation on the basis of data from the Phase 1 BALLI-01 trial. Full Phase 1 data were presented at the European Hematology Association congress the same month: 45 patients treated in third line and beyond, including 15 at the recommended Phase 2 dose and 7 in the target Phase 2 population, a heavily pretreated group with a median of 5 prior lines of therapy in a range of 2 to 11.
In that target population Cellectis reported an overall response rate of 100 percent, 7 of 7, and complete remission or complete remission with incomplete count recovery in 57 percent, 4 of 7, of whom 75 percent were negative for minimal residual disease. All responding patients went on to haematopoietic stem cell transplantation. Grade 3 or higher cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome each occurred in 4 percent of patients, and IEC-HS of grade 3 or higher in 2 percent, with all events resolved.
The pivotal Phase 2 is enrolling. The UK regulator approved initiation in June 2026, and enrolment was authorised in France, Italy and Spain in July 2026. The first interim analysis is expected in the fourth quarter of 2026.
Eti-cel, in relapsed or refractory non-Hodgkin lymphoma, is earlier. As of a February 2026 data cutoff, 14 patients had been treated across three dose levels in the Phase 1 NATHALI-01 trial, with a median of 3 prior lines and 93 percent having received prior CD19-directed CAR-T. In the optimal dose cohort of 8 patients, Cellectis reported an 88 percent overall response rate and a 63 percent complete response rate. Translational data presented at the same congress linked higher alemtuzumab exposure to better eti-cel expansion and higher response rates, which the company said supports a weight-based lymphodepletion regimen now under investigation. The full Phase 1 dataset is expected in the fourth quarter of 2026.
Revenue is collaboration accounting, not product sales
Revenues were 11.0 million dollars for the six months ended June 30, 2026, of which 10.7 million dollars came from performance obligations satisfied under research plans of the joint research and collaboration agreement with AstraZeneca Ireland. The comparable figure a year earlier was 26.9 million dollars, a decrease of 16.4 million dollars that the company attributed to the level of activity performed under those research plans. Second-quarter revenues were 5,229 thousand dollars against 16,725 thousand dollars. The first quarter of 2026 alone had produced 5.8 million dollars of revenue, of which 5.6 million dollars came from the same AstraZeneca research plans, against 10.3 million dollars a year earlier, and cash and cash equivalents stood at 34.8 million dollars with fixed-term bank deposits of 150.6 million dollars as of March 31, 2026, before the deposits were run down over the second quarter.
Net loss attributable to shareholders was 0.39 dollars per basic and diluted share for the half, against 0.42 dollars a year earlier, on a weighted average of 100,587,696 shares. Under the AstraZeneca agreement signed in November 2023, the parties agreed to collaborate on up to 10 candidate products, and an amendment dated November 17, 2025 raised the milestone range to between 80 million dollars and 253 million dollars per candidate from between 70 million dollars and 220 million dollars.
Two separate partnered programmes advanced in July 2026 without Cellectis spending on them, both run by Allogene on Cellectis-derived technology. Allogene said the FDA granted RMAT and Fast Track designations to cema-cel, an anti-CD19 candidate licensed to Servier and sublicensed to Allogene, for large B-cell lymphoma patients who test positive for minimal residual disease after first-line therapy. Separately, Allogene published complete Phase 1 data from the TRAVERSE study of ALLO-316, an anti-CD70 candidate licensed directly to Allogene, showing a 31 percent confirmed response rate at the recommended Phase 2 regimen in Stage IV renal cell carcinoma patients with high CD70 expression. At the annual meeting on June 25, 2026, at which approximately 56 percent of voting rights were exercised, resolutions 1 through 29 were adopted and resolution 30 was rejected.
